Screener
Acadia Pharmaceuticals ACAD Nuplazid — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| NUPLAZID net revenue | $183,132 | $168,479 | $350,056 | $328,199 |
| DAYBUE products net revenue | 124,827 | 96,087 | 225,965 | 180,683 |
| Total revenues | 307,959 | 264,566 | 576,021 | 508,882 |
| Less: | ||||
| Cost of product sales | 12,785 | 8,384 | 24,449 | 17,595 |
| License fees and royalties | 15,531 | 12,350 | 28,658 | 23,531 |
| Research and development expense: | ||||
| External research and development | 55,395 | 54,319 | 104,218 | 109,304 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's nuplazid — revenue?
- Acadia Pharmaceuticals (ACAD) reported nuplazid — revenue of $183.13M in Q2 2026.
- How has Acadia Pharmaceuticals's nuplazid — revenue changed year-over-year?
- Acadia Pharmaceuticals's nuplazid — revenue increased by 8.7% year-over-year, from $168.48M to $183.13M.
- What is the long-term trend for Acadia Pharmaceuticals's nuplazid — revenue?
- Over 3 years (2022 to 2025), Acadia Pharmaceuticals's nuplazid — revenue has grown at a 9.6% compound annual growth rate (CAGR), from $517.24M to $680.09M.
- What does nuplazid — revenue mean?
- This metric represents the total net sales generated from the commercialization of a specific pharmaceutical product, excluding any taxes collected from customers. It serves as a primary indicator of the product's market adoption, pricing power, and overall commercial performance within the company's portfolio. Tracking this revenue stream helps investors evaluate the growth trajectory and lifecycle maturity of the therapeutic asset.
Ask your AI about Acadia Pharmaceuticals's nuplazid — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude